Page 23 - 《中国药房》2025年8期

ces. Patient involvement in the development，regulation 05]. https：//www. fda. gov/industry/prescription-drug-user-
and safe use of medicines[R/OL].[2025-01-09]. https：//ci‐ fee-amendments/condition-specific-meeting-reports-and-
oms.ch/publications/product/patient-involvement/. other-information-related-patients-experience.
[ 4 ] 蒋玉霞，茅宁莹. 欧盟促进患者参与药物研发的实践及 [18] MURPHY A，BERE N，VAMVAKAS S，et al. The added
对我国的启示[J]. 中国新药杂志，2019，28（19）：2312- value of patient engagement in early dialogue at EMA：
2318. scientific advice as a case study[J]. Front Med （Laus‐
[ 5 ] 徐筱蕾，贺宇杉，李军 . “患者参与” 理念内涵及形成过 anne），2022，8：811855.
程概述[J]. 中华医院管理杂志，2018，34（5）：396-399. [19] FDA. Patient engagement collaborative [EB/OL]. （2023-
[ 6 ] Office of Pharmaceutical Industry Research. Thinking 08-14）[2024-09-18]. https：//www.fda.gov/patients/learn-
about “patient and public involvement” in the healthcare about-fda-patient-engagement/patient-engagement-colla-
field[EB/OL]. （2023-03-25）[2025-01-09]. https：//www. borative.
jpma.or.jp/opir/news/058/01.html. [20] FDA. About the FDA patient representative program[EB/
[ 7 ] KISH L. Patient engagement is a strategy，not a tool[R/ OL]. （2023-12-04）[2024-09-18]. https：//www.fda.gov/pa‐
OL]. [2025-01-09]. https：//hl7standards. com/wp-content/ tients/learn-about-fda-patient-engagement/about-fda-patient-
themes/vrxari5pwd76ek0nilkdf102400/files/wp-content/ representative-program.
uploads/2014/11/hl7standards-patient-engagement-ebook. [21] FDA. Charter of the Patient Engagement Advisory Com‐
pdf. mittee to the Food and Drug Administration[EB/OL].
[ 8 ] The European Patients’ Academy.Guidance for patient in‐ （2023-10-05）[2024-09-18].https：//www.fda.gov/advisory-
volvement in regulatory processes[EB/OL].（2023-07-18） committees/patient-engagement-advisory-committee/charter-
[2024-09-18]. https：//toolbox. eupati. eu/resources/patient- patient-engagement-advisory-committee-food-and-drug-
toolbox/guidance-for-patient-involvement-in-regulatory- administration.
processes/. [22] EMA. How the European Medicines Agency interacts with
[ 9 ] 方中坚，沈家辉，汪颖霞，等. 以患者为中心的临床试验 patients and consumers[EB/OL]. （2016-02-04）[2024-09-
18]. https：//www. ema. europa. eu/en/documents/presenta‐
理念及发展趋势探讨[J]. 中国新药杂志，2024，33（13）：
1356-1361. tion/presentation-how-european-medicines-agency-interacts-
[10] 吴晓蕾，史梦龙，张晨瑶，等. 以患者为中心药物研发相 patients-consumers_en.pdf.
[23] EMA. Getting involved in EMA activities as a patient，
关概念介绍[J]. 中国循证医学杂志，2023，23（12）：1472-
1477. consumer or career[EB/OL]. （2024-07-11）[2024-11-06].
[11] DIA Global Forum. Patient engagement that enables regu‐ https：//www.ema.europa.eu/en/partners-networks/patients-
consumers/getting-involved-ema-activities-patient-consumer-
latory decisions[EB/OL]. （2023-03-04） [2024-11-05].
https：//globalforum.diaglobal.org/issue/february-2023/patient- or-career#overview-of-patient-involvement-along-the-
engagement-that-enables-regulatory-decisions/. medicines-lifecycle-at-ema-38705.
[12] 晏利姣，杨思红，HU X Y，等. 如何在临床实践指南制定 [24] EMA. EU innovation network （EU-IN）[EB/OL].（2020-
06-12）[2024-09-18]. https：//www.ema.europa.eu/en/com‐
过程中保证患者及公众的有效参与[J]. 中国循证心血管 mittees/working-parties-other-groups/eu-innovation-
医学杂志，2022，14（9）：1025-1028. network-eu.
[13] FDA. Training and development initiatives[EB/OL].
[25] PPI Japan. Organization overview[EB/OL]. （2023-01-01）
（2019-04-10）[2024-11-05]. https：//www.fda.gov/science- [2024-09-18]. https：//www.ppijapan.org/about.
research/fda-stem-outreach-education-and-engagement/ [26] OGOURTSOVA T，GONZALEZ M，ZERBO A，et al. Les‐
training-and-development-initiatives.
sons learned in measuring patient engagement in a
[14] EMA. Mandate，objectives and composition of the Pa‐ Canada-wide childhood disability network[J]. Res Involv
tients and Consumers Working Party （PCWP）[EB/OL]. Engagem，2024，10（1）：18.
（2019-05-10）[2024-09-18]. https：//www.ema.europa.eu/ [27] 人民日报. “淋巴瘤之家”创始人顾洪飞：让患者组织助
en/documents/other/mandate-objectives-composition-patients-
力政策落地[EB/OL]. （2022-11-19）[2025-01-09]. https：//
consumers-working-party-pcwp_en.pdf. m.peopledailyhealth.com/articleDetailShare articleId=
[15] PMDA. Patient centricity WG[EB/OL]. （2019-05-01） 8edf7bd3b28e450aba76e4922bfa29da.
[2024-09-18]. https：//www.pmda.go.jp/english/rs-sb-std/ [28] 罕见病信息网.中国患者社群组织参与药物研发的现状
rs/0022.html. [EB/OL]. （2023-03-28）[2024-9-11]. https：//mp.weixin.
[16] Around the Globe. Assessing the scope of patient engage‐ qq.com/s/r0eW2mVBxjmaH8QR65m0Tg.
ment in Canada[EB/OL]. [2024-09-18]. https：//globalfo‐ [29] 范子田 . “患者参与”：医疗变革特效药[J]. 中国医院院
rum.diaglobal.org/issue/june-2020/assessing-the-scope-of- 长，2015，11（3）：86-88.
patient-engagement-in-canada/. （收稿日期：2024-09-30 修回日期：2025-01-10）
[17] FDA. Condition-specific meeting reports and other infor‐ （编辑：林 静）
mation related to patients’ experience[EB/OL].[2024-11-

中国药房 2025年第36卷第8期 China Pharmacy 2025 Vol. 36 No. 8 · 913 ·